As shown in Figure 6, indoximod influenced the pathological process of nonalcoholic fatty liver disease through regulated TNFa, AP-1, AKT, PI3K, etc. The results indicated that indoximod may be an effective drug for nonalcoholic fatty liver. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.